HighTide Therapeutics Inc (02511.HK)

Hightide Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders with large and unsatisfied market needs. The company is headquartered in Shenzhen, Guangdong and currently employs 57 full-time employees. The company went IPO on 2023-12-22. The firm has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The firm conducts operations in the United States, Mainland China, Hong Kong and Australia.